Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly beta-lactam-resistant Streptococcus pneumoniae

Antimicrob Agents Chemother. 2007 Sep;51(9):3371-3. doi: 10.1128/AAC.00137-07. Epub 2007 Jun 18.

Abstract

The in vitro and in vivo antipneumococcal activities of the main pneumococcal autolysin (LytA) and Cpl-1, a lysozyme encoded by phage Cp-1, were studied. Intraperitoneal therapy with LytA or high-dose Cpl-1 remarkably reduced peritoneal bacterial counts (>5 log(10) CFU/ml) compared with those for the controls. After intravenous injection, LytA was the most effective treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Ascitic Fluid / microbiology
  • Bacteriophages / genetics
  • Colony Count, Microbial
  • Drug Resistance, Bacterial / drug effects*
  • Injections, Intraperitoneal
  • Injections, Intravenous
  • Mice
  • Microbial Sensitivity Tests
  • Muramidase / therapeutic use
  • N-Acetylmuramoyl-L-alanine Amidase / pharmacology
  • N-Acetylmuramoyl-L-alanine Amidase / therapeutic use*
  • Peritonitis / drug therapy*
  • Peritonitis / etiology
  • Pneumococcal Infections / drug therapy*
  • Pneumococcal Infections / microbiology*
  • Streptococcus pneumoniae / chemistry*
  • Streptococcus pneumoniae / drug effects*
  • beta-Lactams / pharmacology*

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • CPL7 lysozyme
  • Muramidase
  • N-Acetylmuramoyl-L-alanine Amidase